HGHazal Gezmis

Hazal Gezmis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hazal Gezmis has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Tansu Doran

    Department of Medical Biology Faculty of Medicine Yeditepe University Istanbul Turkey

    4 shared publications
  • Deniz Kirac

    Department of Medical Biology Faculty of Medicine Yeditepe University Istanbul Turkey

    3 shared publications
  • Deniz Yucel

    Department of Histology and Embryology Faculty of Medicine Acibadem Mehmet Ali Aydinlar University Istanbul Turkey

    3 shared publications
  • Deniz Kirac

    Faculty of Medicine, Department of Medical Biology, Yeditepe University, Istanbul, Turkey

    2 shared publications
  • Fusun Mayda Domac

    Department of Neurology University of Health SciencesErenkoy Mental and Nervous Diseases Training and Research Hospital Istanbul Turkey

    2 shared publications
  • Rahsan Karaci

    Department of Neurology University of Health SciencesErenkoy Mental and Nervous Diseases Training and Research Hospital Istanbul Turkey

    2 shared publications

Latest Publications

  • Open Access

    Cardiac tissue engineering strategies: Past, present, and future

    by Hazal Gezmis Gokce, Carolyn Carr, Jan Czernuszka

    Cardiovascular diseases remain one of the most challenging health issues of our time. However, with the advancement of various innovative approaches, such as cardiac tissue engineering (CTE), it has become increasingly possible to address this issue. CTE focuses on the development of either a whole organ or a smaller replica known as a cardiac patch, which is implanted into the patient's body to promote tissue regeneration. Over the years, the field has embraced a wide range of methodologies, incorporating various cellular and chemical compositions to improve outcomes, and research continues to evolve. The primary aim of CTE is to understand and effectively harness the complex interactions between materials and cells, ensuring their successful integration within the body. This review highlights the progress made over the past two decades in developing cardiac patches, examining the biomaterials and cell technologies used, their functionality, and the challenges that still need to be addressed.


  • VDBP and VDR Mutations May Cause In-Stent Restenosis

    by Deniz Kiraç, Aysun Erdem Yaman, Hazal Gezmi̇ş, Kemal Yeşi̇lÇi̇mEn, Tuba Avcilar, İlTer Güney, Elif Çiğdem Altunok, Gülşah Koç, Rabican Akkanat, Turgay İşBi̇r

    Objective: In-stent restenosis (ISR) is the narrowing of a stented coronary artery lesion. A considerable number of patients undergoing percutaneous coronary intervention (PCI) are affected by ISR. The predominant mechanism in the development of ISR is an inflammatory response to vessel wall injury during PCI. Vitamin D is reported to have anti-inflammatory properties, so it may also be related with ISR. Therefore, in this study the relationship between vitamin D receptor (VDR), vitamin D binding protein (VDBP) gene variations and ISR were investigated. Methods: Fifty-eight ISR patients who have chest pain, underwent angiography and were found to have restenosis in the previously inserted stent were included in the patient group and thirty-five patients who have chest pain and were not found to have restenosis in their previous stent in coronary angiography were included in the control group. rs7041 and rs4588 variations in VDBP; rs1544410 and rs2228570 variations in VDR were investigated by real-time polymerase chain reaction (RT-PCR). Results were evaluated statistically. Results: The CC genotype of rs2228570 variation of VDR and the CA genotype of rs4588 variation of VDBP were found statistically high in patient group. rs7041 variation was found statistically high in patients who had myocardial infarction history before stent implantation. Additionally, it was demonstrated that vitamin D deficiency (vitamin D level

  • ε 2 , ε 3 , and ε 4 variants of ApoE ; rs2228570 (VDR) , rs4588 and rs7041 (VDBP) polymorphisms in patients with multiple sclerosis: A case–control study in Turkish population

    by Hazal Gezmis, Fusun Mayda Domac, Burcu Ormeci, Handan Uyanik, Tansu Doran, E. Cigdem Keles, Deniz Kirac

    Aim of the Study Multiple sclerosis (MS) is a degenerative disease characterized by autoimmune demyelination in the central nervous system. Yet, underlined genetics or environmental markers are still controversial. The impact of vitamin D and cholesterol on disease activity has been phrased by many studies, however, the data available for the Turkish population is very limited. Here, it is aimed to investigate the effect of vitamin D-related polymorphisms (VDBP and VDR) and cholesterol-related variants of ApoE on Turkish MS patients. Materials & Methods Total DNAs were extracted from peripheral blood samples of fifty-one MS patients and fifty healthy volunteers. rs4588 and rs7041 polymorphisms of VDBP, rs2228570 of VDR, as well as ε2, ε3, and ε4 variants of ApoE, were investigated by RT-PCR. Biochemical parameters which thought to be associated with MS were also measured. Results were evaluated statistically. Results Homozygous mutant genotype and G allele of rs2228570 in VDR, as well as heterozygous genotype of rs4588 in VDBP, were found statistically high in patients. Total cholesterol, triglyceride, and LDL-C levels were found significantly high whereas HDL-C and vitamin D levels were low in patients. An association was found between rs4588 variation and high triglyceride levels. Similar correlations were found between ε2 genotype and low LDL-C level; ε3 genotype and higher LDL-C. Gender, triglyceride, HDL-C, and AA genotype in rs4588 had a significant effect on MS progression. Conclusion The variations of rs2228570 and rs4588, vitamin D deficiency, and biological parameters related to cholesterol metabolism may be associated with MS risk.


  • CD4+ and CD25+ T‐cell response to short‐time interferon‐beta therapy on IL10, IL23A and FOXP3 genes in multiple sclerosis patients

    by Hazal Gezmis, Tansu Doran, Fusun Mayda Domac, Deniz Yucel, Rahsan Karaci, Deniz Kirac

    Aim of the Study Interferon‐beta (IFN‐β), multiple sclerosis (MS) drug for years, does not have therapeutic effects on each patient. Yet, a considerable portion has experienced no therapeutic response to IFN‐β. Therefore, it is necessary to determine disease‐specific biomarkers that affect drug response. Here, we aimed to determine the effects of interleukin 10 (IL10) and 23 (IL23A), as well as forkhead box P3 (FOXP3) genes on MS after IFN‐β therapy. Materials and Methods Peripheral blood mononuclear cells (PBMCs) of 42 MS patients were isolated to obtain CD4+ and CD25+ T cells. Both cell types were characterised by flow cytometry. To determine optimum drug concentration of IFN‐β, cytotoxicity assays were assessed on each cell type for 4, 16, 24 and 48 hours respectively. Then, cells were cultured in the presence of 500 IU/mL of IFN‐β. cDNA synthesis was performed after mRNA extraction. RT‐PCR was performed to measure gene expressions of IL10, IL23A and FOXP3. Results were evaluated statistically. Results It was found that the cytotoxic effect of IFN‐β was more efficient as the exposure time was expanded regardless of drug concentration. Moreover, CD25+ T lymphocytes were more resistant to IFN‐β. IL23A was down‐regulated, whereas FOXP3 was up‐regulated at 48 hours in CD4+ T cells. For CD25+ T cells, the graded increase in FOXP3 was obtained while IL10 expression was gradually decreased throughout the drug intake. Conclusion Although a considerable change in expression was obtained, the long‐term IFN‐β effect on both genes and cells should be determined by follow‐up at least a year.


  • Open Access

    Interferon-beta changes the expression of IL10, IL23A and FOXP3 on Multiple Sclerosis patients' T cells

    by Hazal Gezmis, Tansu Doran, Saime Fusun Mayda Domac, Deniz Yucel, Rahsan Karaci, Deniz Yat

    Aim of the Study: Multiple sclerosis (MS) is an autoimmune disorder causing demyelination in axons. Available therapies target different molecules, but not all have therapeutic effects on disease progression, and this effect can only be seen after a long-time administration. Interferon beta (IFN-β), an MS therapy for many years, slows down the disease progression and reduces disease symptoms by targeting T cells. Yet, a considerable portion of the patient has experienced no therapeutic response to IFN-β. It is necessary to determine disease-specific biomarkers which allow early diagnosis or treatment of MS. Here, it was aimed to determine the effects of interleukin 10 (IL10) and 23 (IL23A) as well as forkhead box P3 (FOXP3) genes on MS after IFN-β therapy. Materials & Methods: Peripheral blood mononuclear cells (PBMCs) were extracted to isolate CD4+ and CD25+ T cells. Cytotoxicity assays were performed on each cell type for determining optimum drug concentration. Then, cells were cultured and determined drug concentration was administered to the cells to measure gene expressions with RT-PCR. Results: It was found that the cytotoxic effect of IFN-β was more efficient as the exposure time was expanded regardless of drug concentration. Moreover, CD25+ T lymphocytes were more resistant to IFN-β. IL23A was down-regulated, whereas FOXP3 was up-regulated at 48h in CD4+ T cells. For CD25+ T cells, the graded increase of FOXP3 was obtained while IL10 expression was gradually decreased throughout the drug intake, significantly. Conclusion: Although considerable change in expression was obtained, the long-term IFN-β effect on both genes and cells should be determined by follow-up at least a year. Keywords: MS, IFN-β, IL23A, FOXP3, IL10, T cells

  • Open Access

    Short-term effect of IFN-β therapy on the expression of IL23A, FOXP3 and IL10 in CD4+ and CD25+ T cells of MS patients

    by Hazal Gezmis, Tansu Doran, Fusun Domac Mayda, Deniz Yucel, Rahsan Oz, Deniz Kirac

    Multiple sclerosis (MS) is an autoimmune disorder causing demyelination in axons. Available therapies target different molecules, but not all have therapeutic effects on disease progression, and this effect can only be seen after a long-time administration. By the time, the disease progresses, and its outcomes become unbearable for the patient. IFN-β has been used in MS therapy for many years. It slows down the disease progression, also reduces disease symptoms by targeting T cells. Yet, a considerable portion of the patient has experienced no therapeutic response to IFN-β. Therefore, it is necessary to determine disease-specific biomarkers which allow early diagnosis or treatment of MS. Here, it was aimed to determine the effects of IL10, IL23A and FOXP3 genes on the therapeutic response to MS after IFN-β administration. PBMCs were extracted from blood samples to isolate CD4+ and CD25+ T cells. Cytotoxicity assays were performed on each cell type for determining optimum drug concentration. Then cells were cultured again and determined drug concentration was administered to the cells to measure gene expressions with RT-PCR. At the end of the study, it was found that the cytotoxic effect of IFN-β was more efficient as the exposure time was expanded regardless of drug concentration. Moreover, CD25+ T lymphocytes were more resistant to IFN-β. IL23A was down-regulated, whereas FOXP3 was up-regulated at 48h in CD4+ T cells. For CD25+ T cells, the graded increase of FOXP3 was obtained while IL10 expression was gradually decreased throughout the drug intake, which both were statistically significant.

  • Open Access

    Türk Atletlerde D Vitamini Reseptör Geni Fok1 (rs2228570) ve Bsm1 (rs1544410) Polimorfizmlerinin Analizi

    by Basak Funda Eken, Hazal Gezmi̇ş, Canan Sercan, Sezgin Kapici, Özlem Moufti Chousein, Deniz Kiraç, Serap Akyüz, Korkut Ulucan

    Amaç: D vitamini kasların gelişmesinde, kasılmasında ve rejenerasyonunda görev alan önemli bir moleküldür. Çalışmamızda profesyonel Türk atletlerde D vitamin reseptör (VDR) Fok1 (rs 2228570) ve Bsm1 (rs1544410) polimorfizmlerinin dağılımını araştırmayı amaçladık. Yöntem: Çalışmamıza 13 kadın ve 14 erkek atlet olmak üzere 27 sporcu katılmıştır. DNA izolasyonları sonrasında D vitamini reseptörü polimorfizmleri gerçek zamanlı PZR (RT-PCR) metodu ile saptanmıştır. Bulgular: Fok1 polimorfizmi açısından atletlerin 12’si CC, 5’i CT ve 10’u ise TT genotipindedir. Kadın atletlerin 6’sı CC, 2’si CT ve 5’i ise TT genotipinde bulunmuştur. Erkek atletlerde 6 sporcu CC, 3 sporcu CT ve 5 sporcu ise TT genotipindedir. Bsm1 polimorfizmi için 9 atlet AA, 14'ü AG, 4’ü ise GG genotipindedir. Kadın atletlerin 3’ü AA, 8’i AG ve 2’si GG genotipindedir. Erkek atletlerin 6’sı AA, 6’sı AG ve 2’si GG genotipinde saptanmıştır. Sonuç: Çalışma grubumuzda Fok1 polimorfizmi için CC genotipi ve C allelinin, Bsm1 içinde AG genotipinin ve A allelinin baskın olduğu gözlenmiştir. Bu çalışmanın VDR geninin atletik performansa etkisinin araştırılması için yapılacak yeni çalışmalar için referans olacağını düşünmekteyiz.